The “Best of Antiangiogenesis” is a series of ten webcasts featuring presentations from leading medical experts describing research and perspectives on new angiogenesis-based therapies. 

These webcast presentations are derived from the Angiogenesis Foundation’s 8th Annual M. Judah Folkman Antiangiogenesis Conference, held October 8-9, 2010 in Cambridge, Massachusetts.

The presentations were originally intended for a professional audience so may be technical in content. The information contained in these webcasts is in no way meant to substitute for medical care.

Prior to viewing a webcast, you will be asked to complete a brief registration form. This information is for internal use by the Angiogenesis Foundation only, and will not be sold or distributed. You will only be required to register once for the program.

For CME credit, please read the below information before proceeding.

ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
PROGRAMS AND FACULTY
 
Dietary Impact on Cancer Epigenetics and Angiogenesis
Nancy Emenaker, Ph.D., R.D.
Program Director
National Cancer Institute/National Institutes of Health
CME Course Code: I.ANG11bstdiet
 
Clinical Markers of Antiangiogenic Therapy in the Platelet Proteome
Giannoula Lakka Klement, M.D., FRCPC
Assistant Professor in Medicine
Tufts University School of Medicine
CME Course Code: I.ANG11bstplate
 
Sequential Angiogenenic Blockade for the Treatment of Recurrent Cancer
Joyce F. Liu, M.D., M.P.H.
Instructor of Medicine
Dana Farber Cancer Institute
CME Course Code: I.ANG11bstblock
 
Controversies of Anti-VEGF Therapy for Breast Cancer
Erica L. Mayer, M.D., M.P.H.
Instructor in Medicine
Harvard Medical School Dana Farber Cancer Institute
CME Course Code: I.ANG11bstvegf
 
Intergrin Targeting for Advanced Malignancies
David A. Reardon, M.D.
Associate Professor
Duke University Medical Center
CME Course Code: I.ANG11bstadv
 
Antiangiogenic Therapy Response vs. Pseudoresponse in Brain Cancer
A. Gregory Sorensen, M.D.
Co-Director, Martinos Center for Biomedical Imaging Massachusetts General Hospital
CME Course Code: I.ANG11bstbc
 
Endothelial Progenitor Cells as Systemic Sensors of Breast Cancer
Raj K, Tiwari, Ph.D.
Professor of Microbiology and Immunology
New York Medical College
CME Course Code: I.ANG11bstendo
 
Biomarker Identification in Antiangiogenesis Clinical Trials
Peter M. Wilson, Ph.D.
Doctoral Research Associate
Keck School of Medicine
USC Norris Comprehensive Cancer Center
CME Course Code: I.ANG11bstid
 
CREDIT DESIGNATION
This CME Internet activity is comprised of a series of 8 individual webcasts. Boston University School of Medicine designates each webcast a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
 
RELEASE AND EXPIRATION
Date of original release: July 8, 2011
Date of expiration: July 7, 2012
 
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
 
HEALTHCARE GAP

Even with approved agents on the market, antiangiogenic therapy represents a relatively new approach to cancer management, which leads to a critical need to rapidly and effectively educate physicians about: the scientific and clinical rationale for treating tumor angiogenesis; the pathways and mechanisms involved in tumor angiogenesis; the strategies by which antiangiogenic agents are being integrated into traditional therapeutic protocols; the efficacy and safety data emerging from well-designed and rigorous clinical studies of antiangiogenic therapy; and how this data can directly be used to improve clinical decision-making and outcomes for cancer patients. In addition, many clinicians were trained before the era of targeted therapies and can be overwhelmed with the intricacies of signal pathways, their interrelationships, and the effects of therapies. Therefore, there is an opportunity to educate clinicians about this complex information using visual graphic communication tools.
 
PROGRAM LEARNING OBJECTIVES
At the conclusion of this educational activity, clinicians will be able to:

• Summarize angiogenesis-based targets for treating angiogenesis-dependent diseases that improve patient outcomes
• Discuss recent clinical data supporting the use of emerging and approved angiogenesis-based treatments that benefit patients and their advocates
• Interpret safety and efficacy data from advanced and pivotal clinical trials of angiogenesis-based therapies
• Describe and differentiate new strategies integrating angiogenesis agents with current therapies